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Background: We hypothesized atorvastatin, particularly at high dose, may increase insulin levels and worsen glucose metabolism with reducing 
plasma levels of adiponectin and insulin sensitivity in hypercholesterolemic patients.
Methods: This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched. Forty-four patients 
were given on placebo and 42, 44, 43, and 40 patients were given daily on atorvastatin 10, 20, 40, and 80 mg, respectively during a 2 month 
treatment period.
Results: Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol (mean % changes; 39, 47, 52, and 56%) and apolipoprotein B 
levels (33, 37, 42, and 46%) after 2 months therapy when compared with baseline (all P<0.001 by paired t-test) or when compared with placebo 
(P<0.001 by ANOVA). Atorvastatin 10, 20, 40, and 80 mg significantly increased insulin (25, 42, 31, and 45%) and glycated hemoglobin levels (2, 5, 
5, and 5%) from baseline (all P<0.05 by paired t-test) or when compared with placebo (P=0.009 for insulin and P=0.008 for glycated hemoglobin by 
ANOVA). Atorvastatin 10, 20, 40, and 80 mg decreased plasma adiponectin levels (4, 10, 3, and 9%) and decreased insulin sensitivity (1, 3, 3, and 
4%) when compared with baseline (P=0.124, P=0.004, P=0.084, and P=0.040 for adiponectin; P=0.312, P=0.008, P<0.001, and P=0.008 for insulin 
sensitivity by paired t-test) or when compared with placebo (P=0.183 for adiponectin and P=0.033 for insulin sensitivity by ANOVA). However, the 
magnitude of these percent changes (glycated hemoglobin, insulin, adiponectin, and QUICKI) were not significantly different among the four different 
doses of atorvastatin despite dose-dependent changes in LDL cholesterol and apolipoprotein B reduction.
Conclusions: Atorvastatin significantly increased insulin and glycated hemoglobin levels and reduced insulin sensitivity in hypercholesterolemic 
patients independent of dosage and the extent of LDL cholesterol and apolipoprotein B reduction.
